Rein Therapeutics, Inc. (RNTX)
RNTX moved a median of -0.90% 30 minutes after news, and -0.57% by the close. How RNTX actually reacts to news — the realized, point-in-time move the market made, measured across 102 labeled events over the last three years with zero look-ahead.
RNTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 22% | 86 |
| 30-min | -0.90% | 29% | 99 |
| 60-min | -0.24% | 36% | 102 |
| to close | -0.57% | 42% | 100 |
| Middle 50% of RNTX reactions | -2.85% to +0.37% |
|---|---|
| Median reaction (30-min) | -0.90% |
| Measured reactions | 102 |
Half of all Rein Therapeutics, Inc. news events land between -2.85% and +0.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RNTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RNTX's baseline. Nothing else.
Recent RNTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Rein Therapeutics, Inc. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -7.26% | |
| Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress | Press release | GlobeNewswire | -5.41% | -3.36% | |
| Rein Therapeutics to Present at Upcoming September Investor Conferences | Press release | GlobeNewswire | -5.41% | -3.36% | |
| Form 8-K Rein Therapeutics, Inc. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -3.34% | |
| Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -1.91% | -7.32% | |
| Form 10-Q Rein Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.60% | -0.49% | |
| Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.60% | -0.49% | |
| Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications | Press release | GlobeNewswire | +0.00% | +0.49% | |
| Form 8-K Rein Therapeutics, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -6.67% | |
| Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries | Press release | GlobeNewswire | -1.87% | +5.27% | |
| Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom | Press release | GlobeNewswire | -1.10% | +1.71% | |
| Form ARS Rein Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.41% | -0.70% | |
| Form DEF 14A Rein Therapeutics, Inc. For: Jul 20 | SEC filing · Form DEF | SEC EDGAR | -3.41% | -0.70% | |
| Form DEFA14A Rein Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -3.41% | -0.70% | |
| Form PRE 14A Rein Therapeutics, Inc. For: Jul 20 | SEC filing · Form PRE | SEC EDGAR | +2.70% | +0.00% | |
| Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option | Press release | GlobeNewswire | -3.64% | -5.46% | |
| Form 10-Q Rein Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.91% | -4.54% | |
| Form 8-K Rein Therapeutics, Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -2.86% | |
| Form EFFECT Rein Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.48% | -0.48% | |
| Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock | Press release | GlobeNewswire | -2.73% | -6.36% | |
| Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -0.78% | -1.16% | |
| Form S-1 Rein Therapeutics, Inc. | SEC filing · Form S-1 | SEC EDGAR | -0.78% | -1.16% | |
| Form 10-K/A Rein Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -9.15% | |
| Form 10-K Rein Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.21% | +0.81% | |
| Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -1.70% | -2.54% | |
| Form 8-K Rein Therapeutics, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.59% | |
| Form 8-K Rein Therapeutics, Inc. For: Feb 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +11.01% | |
| Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | +4.26% | +7.14% | |
| Form 8-K Rein Therapeutics, Inc. For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | +4.26% | +7.14% | |
| Form 8-K Rein Therapeutics, Inc. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.31% | |
| Form 10-Q Rein Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.42% | +0.81% | |
| Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF | Press release | GlobeNewswire | -0.65% | +1.30% | |
| Form 8-K Rein Therapeutics, Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -1.48% | +3.55% | |
| Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -1.48% | +3.55% | |
| Form 8-K Rein Therapeutics, Inc. For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | +1.98% | -9.40% | |
| Form 8-K Rein Therapeutics, Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -2.88% | -1.44% | |
| Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -2.88% | -1.44% | |
| Form 8-K Rein Therapeutics, Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | -2.48% | |
| Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | — | +0.00% | |
| Form 8-K Rein Therapeutics, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.51% | -0.76% | |
| Form EFFECT Rein Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.00% | |
| Form S-1 Rein Therapeutics, Inc. | SEC filing · Form S-1 | SEC EDGAR | +4.84% | +10.08% | |
| Form 8-K Rein Therapeutics, Inc. For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -2.50% | — | |
| Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -2.50% | — | |
| Form 10-Q Rein Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.87% | +3.83% | |
| Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 | Press release | GlobeNewswire | -0.87% | +3.83% | |
| Form 8-K Rein Therapeutics, Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | — | -5.93% | |
| Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing | Press release | GlobeNewswire | — | -5.93% | |
| Form 8-K Rein Therapeutics, Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.39% | |
| Form 8-K Rein Therapeutics, Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | — | +7.14% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RNTX section they belong to.
Where else RNTX is measured.
RNTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rein Therapeutics, Inc.'s median reaction calculated?
Every labeled RNTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 102 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 29% of RNTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RNTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.